ICYMI: Amazon Pharmacy adds Zepbound KwikPen at $299 as GLP-1 race heats up: Amazon Pharmacy expands access to Eli Lilly's Zepbound KwikPen at $299/month, combining transparent pricing, same-day delivery, and GLP-1 savings for U.S. customers. https://ppc.land/amazon-pharmacy-adds-zepbound-kwikpen-at-299-as-glp-1-race-heats-up/ #AmazonPharmacy #Zepbound #KwikPen #GLP1 #EliLilly
Amazon Pharmacy adds Zepbound KwikPen at $299 as GLP-1 race heats up

Amazon Pharmacy expands access to Eli Lilly's Zepbound KwikPen at $299/month, combining transparent pricing, same-day delivery, and GLP-1 savings for U.S. customers.

PPC Land
Amazon Pharmacy adds Zepbound KwikPen at $299 as GLP-1 race heats up: Amazon Pharmacy expands access to Eli Lilly's Zepbound KwikPen at $299/month, combining transparent pricing, same-day delivery, and GLP-1 savings for U.S. customers. https://ppc.land/amazon-pharmacy-adds-zepbound-kwikpen-at-299-as-glp-1-race-heats-up/ #AmazonPharmacy #Zepbound #GLP1 #Healthcare #DiabetesManagement
Amazon Pharmacy adds Zepbound KwikPen at $299 as GLP-1 race heats up

Amazon Pharmacy expands access to Eli Lilly's Zepbound KwikPen at $299/month, combining transparent pricing, same-day delivery, and GLP-1 savings for U.S. customers.

PPC Land
Como os medicamentos para obesidade silenciam o “ruído alimentar” no cérebro

Os professores Fernanda Scagliusi e Carlos Negrato explicam estudos recentes sobre os efeitos colaterais das canetas emagrecedoras

Jornal da USP

WHO發布指南建議使用「GLP-1類藥物」治療成人肥胖症,2030年全球20億人過重

julia 2025-12-03 10:03:00 CST世界衛生組織(WHO)發布指南,建議成人肥胖症可長期使用GLP-1類藥物,搭配健康飲食與規律運動,將其作為慢性病管理。此舉標誌著治療思維的轉變,旨在優先處理肥胖症而非其併發症。
https://www.thenewslens.com/article/261916
#Zepbound #GLP-1類藥物 #Wegovy #Saxenda #慢性疾病 #治療指南 #週纖達 #善纖達 #糖尿病 #健康 #瘦瘦筆 #瘦瘦針 #肥胖症 #替爾泊肽 #WHO #世界衛生組織

WHO發布指南建議使用「GLP-1類藥物」治療成人肥胖症,2030年全球20億人過重 - TNL The News Lens 關鍵評論網

世界衛生組織(WHO)發布指南,建議成人肥胖症可長期使用GLP-1類藥物,搭配健康飲食與規律運動,將其作為慢性病管理。此舉標誌著治療思維的轉變,旨在優先處理肥胖症而非其併發症。

TNL The News Lens 關鍵評論網
There may not be a safe way to stop taking GLP-1 drugs such as Zepbound, a prescription weight loss medicine #health #science #data #Zepbound arstechnica.com/health/2025/...

There may not be a safe off-ra...
There may not be a safe off-ramp for some taking GLP-1 drugs, study suggests

In trial, 82% saw weight rebound and cardiovascular health reverse after withdrawal.

Ars Technica
“Our findings raise the possibility that this delta–theta band oscillation could serve as a target engagement biomarker, but its relationship to food preoccupation warrants more controlled investigation," the authors of the study conclude. #DNA #ISOGG #mounjaro #zepbound #diabetes #tirzepetide #epigenetics
https://www.nature.com/articles/s41591-025-04035-5
Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide - Nature Medicine

This study provides the first evidence in humans that tirzepatide modulates brain electrophysiology, with changes in low-frequency accumbens power linked to food preoccupation.

Nature

The finding that tirzepatide can quiet “food noise” is remarkable. Imagine having similarly precise treatments for other intrusive or compulsive mental states, like those seen across many anxiety disorders.

#GLP1
#Mounjaro
#Zepbound

https://www.nature.com/articles/d41586-025-03766-2

How obesity drugs quiet ‘food noise’ in the brain

Researchers have identified a neural biomarker of compulsive food cravings, and showed that it is suppressed by the weight-loss drug Mounjaro.

Obesity drug seen as effective for long COVID, gets clinical trial

COVID-19 symptoms that don’t go away affect hundreds of millions worldwide. Scripps Research is recruiting people with long COVID to test a weight-loss medication that shows promise in treating the illness.

KPBS
Questions swirl after Trump’s GLP-1 pricing deal announcement https://arstechni.ca/PaYN #NovoNordisk #elililly #mounjaro #zepbound #Ozempic #pricing #Health #wegovy #GLP-1 #Trump #drug
Questions swirl after Trump’s GLP-1 pricing deal announcement

It’s unclear how much savings the deal provides or how many people will benefit.

Ars Technica